JP2018021046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018021046A5 JP2018021046A5 JP2017155657A JP2017155657A JP2018021046A5 JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5 JP 2017155657 A JP2017155657 A JP 2017155657A JP 2017155657 A JP2017155657 A JP 2017155657A JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- dosage form
- unit dosage
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- -1 1-naphth-2-ylethyl Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91932307P | 2007-03-20 | 2007-03-20 | |
| US60/919,323 | 2007-03-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015211991A Division JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018021046A JP2018021046A (ja) | 2018-02-08 |
| JP2018021046A5 true JP2018021046A5 (OSRAM) | 2018-06-14 |
| JP6448726B2 JP6448726B2 (ja) | 2019-01-09 |
Family
ID=39719168
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2017155657A Active JP6448726B2 (ja) | 2007-03-20 | 2017-08-10 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US8153659B2 (OSRAM) |
| EP (2) | EP2142534B1 (OSRAM) |
| JP (4) | JP2010522170A (OSRAM) |
| KR (3) | KR20090121400A (OSRAM) |
| CN (2) | CN101679380A (OSRAM) |
| AR (1) | AR065810A1 (OSRAM) |
| AU (1) | AU2008229383B2 (OSRAM) |
| BR (1) | BRPI0809011A8 (OSRAM) |
| CA (1) | CA2681633C (OSRAM) |
| CL (1) | CL2008000805A1 (OSRAM) |
| CO (1) | CO6231033A2 (OSRAM) |
| CR (2) | CR11036A (OSRAM) |
| EC (1) | ECSP099663A (OSRAM) |
| ES (2) | ES2734253T3 (OSRAM) |
| IL (1) | IL200990A (OSRAM) |
| MX (1) | MX2009010082A (OSRAM) |
| MY (1) | MY180812A (OSRAM) |
| NI (1) | NI200900170A (OSRAM) |
| NZ (2) | NZ599199A (OSRAM) |
| PE (1) | PE20081894A1 (OSRAM) |
| RU (1) | RU2471794C2 (OSRAM) |
| UA (1) | UA97976C2 (OSRAM) |
| UY (1) | UY30977A1 (OSRAM) |
| WO (1) | WO2008115516A2 (OSRAM) |
| ZA (1) | ZA200906497B (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
| WO2006060507A2 (en) * | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| MX2009010082A (es) * | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
| CA2710196A1 (en) | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| EP2521724B1 (en) | 2009-12-11 | 2016-11-23 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2016203826B2 (en) * | 2010-02-11 | 2018-05-17 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2013245487B2 (en) * | 2010-02-11 | 2016-03-10 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| EP2720695A4 (en) * | 2011-06-15 | 2014-11-12 | Nono Inc | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES |
| CN102731850B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油耐磨橡胶 |
| CN102731853B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油橡胶 |
| CN102731851B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 一种耐油橡胶 |
| JP2015524811A (ja) * | 2012-07-27 | 2015-08-27 | セルジーン コーポレイション | イソインドリン−１，３−ジオン化合物の調製プロセス |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| CN114939119A (zh) | 2012-08-09 | 2022-08-26 | 细胞基因公司 | 免疫相关和炎性疾病的治疗 |
| SI2882442T1 (sl) * | 2012-08-09 | 2021-11-30 | Celgene Corporation | Metode zdravljenja raka z uporabo 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin- 2,6-diona |
| EP2882736B1 (en) | 2012-08-09 | 2019-01-09 | Celgene Corporation | Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
| WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| KR102223060B1 (ko) | 2013-04-17 | 2021-03-05 | 시그날 파마소티칼 엘엘씨 | 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법 |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| JP2017522270A (ja) | 2014-05-19 | 2017-08-10 | セルジーン コーポレイション | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| PT3643709T (pt) * | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Ltd | Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10159665B2 (en) | 2016-03-23 | 2018-12-25 | Louis Habash | Preventing amyloid plaque formation by treating a human subject with a nitroxide |
| WO2017165572A1 (en) * | 2016-03-23 | 2017-09-28 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
| US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
| US20180078539A1 (en) | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| AU2017376704B2 (en) * | 2016-12-16 | 2021-08-05 | Kangpu Biopharmaceuticals, Ltd. | Composition, application thereof and treatment method |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| HRP20241553T1 (hr) | 2017-07-10 | 2025-01-17 | Celgene Corporation | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-l-oksoizoindolin-4-il)oksi)metil)benzil)piperazin-l-il)-3-fluorobenzonitril kao antiproliferativni spoj |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
| WO2019043214A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
| WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| AU2019251151B2 (en) * | 2018-04-09 | 2022-07-07 | Shanghaitech University | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| CA3096404A1 (en) | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| EP3820573B1 (en) * | 2018-07-10 | 2023-08-09 | Novartis AG | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| EP3862348A4 (en) * | 2018-09-30 | 2022-06-22 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | ISOINDOLINE COMPOUND, PROCESS OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| KR20210069642A (ko) | 2018-10-01 | 2021-06-11 | 셀진 코포레이션 | 암 치료를 위한 병용 요법 |
| US20220001018A1 (en) * | 2018-11-01 | 2022-01-06 | Northwestern University | Targeting pleckstrin-2 for treating cancer |
| EP3891128A4 (en) * | 2018-12-05 | 2022-08-17 | Vividion Therapeutics, Inc. | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT |
| EP3896062A4 (en) | 2018-12-06 | 2022-06-15 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF ISOINDOLINE COMPOUND |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| CN114144184B (zh) * | 2019-02-22 | 2024-03-29 | 埃肯有机硅美国公司 | 改进活性成分流出的药物递送有机硅组合物 |
| CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
| EA202192738A1 (ru) | 2019-04-12 | 2022-03-17 | С4 Терапьютикс, Инк. | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| WO2021170021A1 (zh) * | 2020-02-25 | 2021-09-02 | 上海科技大学 | 基于戊二酰亚胺骨架的化合物及其应用 |
| JP2023523545A (ja) * | 2020-04-17 | 2023-06-06 | エサイエント ファーマシューティカルズ，インコーポレイティド | Ｍａｓ関連Ｇタンパク質受容体Ｘ４のモジュレーター、関連製品及びその使用方法 |
| JP2023534528A (ja) * | 2020-07-20 | 2023-08-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
| WO2022148358A1 (zh) * | 2021-01-05 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| MX2024008959A (es) | 2022-01-19 | 2024-07-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Forma cristalina de derivado de isoindolina que contiene azufre. |
| KR20250021314A (ko) | 2022-06-06 | 2025-02-12 | 씨4 테라퓨틱스, 인코포레이티드 | 비시클릭-치환된 글루타르이미드 세레블론 결합제 |
| US20240208937A1 (en) | 2022-11-04 | 2024-06-27 | Bristol-Myers Squibb Company | Compounds and Their Use for Treatment of Hemoglobinopathies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
| TR200101504T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CA2538864C (en) * | 2003-09-17 | 2013-05-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| WO2006060507A2 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| AU2005317868B2 (en) * | 2004-12-24 | 2009-06-04 | Astrazeneca Ab | Amide derivatives |
| MX2009010082A (es) * | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
-
2008
- 2008-03-19 MX MX2009010082A patent/MX2009010082A/es active IP Right Grant
- 2008-03-19 EP EP08726977.5A patent/EP2142534B1/en active Active
- 2008-03-19 RU RU2009138500/04A patent/RU2471794C2/ru active
- 2008-03-19 AU AU2008229383A patent/AU2008229383B2/en active Active
- 2008-03-19 AR ARP080101179A patent/AR065810A1/es not_active Application Discontinuation
- 2008-03-19 ES ES16170365T patent/ES2734253T3/es active Active
- 2008-03-19 US US12/077,715 patent/US8153659B2/en active Active
- 2008-03-19 KR KR1020097021797A patent/KR20090121400A/ko not_active Ceased
- 2008-03-19 CA CA2681633A patent/CA2681633C/en active Active
- 2008-03-19 MY MYPI20093935A patent/MY180812A/en unknown
- 2008-03-19 ES ES08726977.5T patent/ES2601131T3/es active Active
- 2008-03-19 CN CN200880016715A patent/CN101679380A/zh active Pending
- 2008-03-19 UA UAA200910592A patent/UA97976C2/ru unknown
- 2008-03-19 NZ NZ599199A patent/NZ599199A/xx not_active IP Right Cessation
- 2008-03-19 CN CN201310547773.7A patent/CN103641814A/zh active Pending
- 2008-03-19 BR BRPI0809011A patent/BRPI0809011A8/pt not_active Application Discontinuation
- 2008-03-19 NZ NZ579890A patent/NZ579890A/en not_active IP Right Cessation
- 2008-03-19 WO PCT/US2008/003602 patent/WO2008115516A2/en not_active Ceased
- 2008-03-19 JP JP2009554563A patent/JP2010522170A/ja not_active Withdrawn
- 2008-03-19 EP EP16170365.7A patent/EP3101017B1/en active Active
- 2008-03-19 KR KR1020177021704A patent/KR20170093996A/ko not_active Ceased
- 2008-03-19 KR KR1020157009558A patent/KR101791757B1/ko active Active
- 2008-03-20 CL CL2008000805A patent/CL2008000805A1/es unknown
- 2008-03-24 UY UY30977A patent/UY30977A1/es not_active Application Discontinuation
- 2008-03-24 PE PE2008000525A patent/PE20081894A1/es not_active Application Discontinuation
-
2009
- 2009-09-16 IL IL200990A patent/IL200990A/en not_active IP Right Cessation
- 2009-09-17 ZA ZA2009/06497A patent/ZA200906497B/en unknown
- 2009-09-18 NI NI200900170A patent/NI200900170A/es unknown
- 2009-09-21 CR CR11036A patent/CR11036A/es unknown
- 2009-09-30 EC EC2009009663A patent/ECSP099663A/es unknown
- 2009-09-30 CO CO09106869A patent/CO6231033A2/es not_active Application Discontinuation
-
2012
- 2012-03-01 US US13/410,216 patent/US8614328B2/en not_active Ceased
-
2013
- 2013-11-18 US US14/083,205 patent/US9181216B2/en active Active
-
2014
- 2014-06-25 JP JP2014129790A patent/JP5927241B2/ja active Active
- 2014-07-16 US US14/333,454 patent/USRE46639E1/en active Active
- 2014-08-01 CR CR20140368A patent/CR20140368A/es unknown
-
2015
- 2015-10-02 US US14/874,318 patent/US9920027B2/en active Active
- 2015-10-28 JP JP2015211991A patent/JP6373818B2/ja active Active
-
2017
- 2017-08-10 JP JP2017155657A patent/JP6448726B2/ja active Active
-
2018
- 2018-02-02 US US15/887,838 patent/US10385037B2/en active Active